D-Index & Metrics Best Publications

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Microbiology D-index 48 Citations 7,641 168 World Ranking 2410 National Ranking 70

Overview

What is he best known for?

The fields of study he is best known for:

  • Virus
  • Gene
  • Antibody

Xiangguo Qiu spends much of his time researching Virology, Ebola virus, Antibody, Monoclonal antibody and Immunology. His Virology research includes themes of Epitope and Glycoprotein. His research in Ebola virus is mostly concerned with Ebolavirus.

The concepts of his Antibody study are interwoven with issues in ZMapp and Bundibugyo virus. His study explores the link between Monoclonal antibody and topics such as Neutralization that cross with problems in Vero cell, Dengue virus, Viral membrane and Natural killer cell. His work in Virus tackles topics such as Outbreak which are related to areas like Chinese hamster ovary cell.

His most cited work include:

  • Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp (722 citations)
  • Successful Treatment of Ebola Virus–Infected Cynomolgus Macaques with Monoclonal Antibodies (264 citations)
  • Nanozyme-strip for rapid local diagnosis of Ebola. (160 citations)

What are the main themes of his work throughout his whole career to date?

The scientist’s investigation covers issues in Virology, Ebola virus, Ebolavirus, Virus and Antibody. Xiangguo Qiu interconnects Immune system, Immunology and Monoclonal antibody in the investigation of issues within Virology. Xiangguo Qiu has researched Ebola virus in several fields, including Transmission, Viremia, Immunity and Glycoprotein.

His study in the field of Bundibugyo virus and Marburgvirus also crosses realms of Filoviridae. His research in Virus focuses on subjects like Viral vector, which are connected to DNA vaccination. His study in Antibody is interdisciplinary in nature, drawing from both ZMapp and In vitro.

He most often published in these fields:

  • Virology (141.01%)
  • Ebola virus (116.29%)
  • Ebolavirus (54.49%)

What were the highlights of his more recent work (between 2018-2021)?

  • Virology (141.01%)
  • Ebola virus (116.29%)
  • Virus (53.93%)

In recent papers he was focusing on the following fields of study:

Xiangguo Qiu focuses on Virology, Ebola virus, Virus, Antibody and Monoclonal antibody. His work deals with themes such as Glycoprotein, Immune system and Antigen, which intersect with Virology. His Ebola virus study is associated with Outbreak.

Xiangguo Qiu studies Neutralization which is a part of Antibody. His studies in Monoclonal antibody integrate themes in fields like Epitope and In vivo. His Ebolavirus study combines topics from a wide range of disciplines, such as Pathogenesis and Immunotherapy.

Between 2018 and 2021, his most popular works were:

  • Development of a Human Antibody Cocktail that Deploys Multiple Functions to Confer Pan-Ebolavirus Protection (38 citations)
  • Development of a Human Antibody Cocktail that Deploys Multiple Functions to Confer Pan-Ebolavirus Protection (38 citations)
  • A Two-Antibody Pan-Ebolavirus Cocktail Confers Broad Therapeutic Protection in Ferrets and Nonhuman Primates (35 citations)

In his most recent research, the most cited papers focused on:

  • Virus
  • Gene
  • Antibody

Xiangguo Qiu mainly investigates Ebola virus, Virology, Virus, Antibody and Ebolavirus. His research in Ebola virus intersects with topics in Nucleoprotein and Immunotherapy. His biological study spans a wide range of topics, including Ebola vaccine, Viral Vaccine, Immunogen and Antigen.

His Immunotherapy study often links to related topics such as Monoclonal antibody. His Vaccination and Antiviral drug study in the realm of Virology connects with subjects such as Post exposure. His research integrates issues of Immune system, Immunity, Immunogenicity, Viral vector and DNA vaccination in his study of Vaccination.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp

Xiangguo Qiu;Gary Wong;Jonathan Audet;Alexander Bello.
Nature (2014)

1031 Citations

Successful Treatment of Ebola Virus–Infected Cynomolgus Macaques with Monoclonal Antibodies

Xiangguo Qiu;Jonathan Audet;Gary Wong;Stephane Pillet.
Science Translational Medicine (2012)

351 Citations

Nanozyme-strip for rapid local diagnosis of Ebola.

Demin Duan;Kelong Fan;Dexi Zhang;Shuguang Tan.
Biosensors and Bioelectronics (2015)

205 Citations

Structures of protective antibodies reveal sites of vulnerability on Ebola virus

Charles D. Murin;Marnie L. Fusco;Zachary A. Bornholdt;Xiangguo Qiu.
Proceedings of the National Academy of Sciences of the United States of America (2014)

188 Citations

Molecular determinants of human neutralizing antibodies isolated from a patient infected with Zika virus

Qihui Wang;Huabing Yang;Huabing Yang;Xiaoqing Liu;Lianpan Dai.
Science Translational Medicine (2016)

170 Citations

Immune Parameters Correlate with Protection Against Ebola Virus Infection in Rodents and Nonhuman Primates

Gary Wong;Jason S. Richardson;Stéphane Pillet;Ami Patel;Ami Patel.
Science Translational Medicine (2012)

161 Citations

Dlx1, Dlx2, Pax6, Brn3b, and Chx10 homeobox gene expression defines the retinal ganglion and inner nuclear layers of the developing and adult mouse retina.

Jimmy de Melo;Xiangguo Qiu;Guoyan Du;Leah Cristante.
The Journal of Comparative Neurology (2003)

151 Citations

Characterization of Zaire ebolavirus glycoprotein-specific monoclonal antibodies.

Xiangguo Qiu;Judie B. Alimonti;Judie B. Alimonti;P. Leno Melito;Lisa Fernando.
Clinical Immunology (2011)

151 Citations

Mucosal Immunization of Cynomolgus Macaques with the VSVΔG/ZEBOVGP Vaccine Stimulates Strong Ebola GP-Specific Immune Responses

Xiangguo Qiu;Lisa Fernando;Judie B. Alimonti;Judie B. Alimonti;P. Leno Melito.
PLOS ONE (2009)

149 Citations

mAbs and Ad-Vectored IFN-α Therapy Rescue Ebola-Infected Nonhuman Primates When Administered After the Detection of Viremia and Symptoms

Xiangguo Qiu;Gary Wong;Gary Wong;Lisa Fernando;Jonathan Audet;Jonathan Audet.
Science Translational Medicine (2013)

142 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Xiangguo Qiu

Heinz Feldmann

Heinz Feldmann

National Institutes of Health

Publications: 78

Thomas W. Geisbert

Thomas W. Geisbert

The University of Texas Medical Branch at Galveston

Publications: 55

Andrea Marzi

Andrea Marzi

National Institutes of Health

Publications: 43

John M. Dye

John M. Dye

United States Army Medical Research Institute of Infectious Diseases

Publications: 41

James E. Crowe

James E. Crowe

Vanderbilt University Medical Center

Publications: 40

Erica Ollmann Saphire

Erica Ollmann Saphire

La Jolla Institute For Allergy & Immunology

Publications: 38

George F. Gao

George F. Gao

Chinese Center For Disease Control and Prevention

Publications: 37

Sina Bavari

Sina Bavari

United States Army Medical Research Institute of Infectious Diseases

Publications: 35

Alexander Bukreyev

Alexander Bukreyev

The University of Texas Medical Branch at Galveston

Publications: 35

Galit Alter

Galit Alter

Ragon Institute of MGH, MIT and Harvard

Publications: 33

Gary Kobinger

Gary Kobinger

Université Laval

Publications: 31

Kartik Chandran

Kartik Chandran

Albert Einstein College of Medicine

Publications: 28

Lisa E. Hensley

Lisa E. Hensley

National Institutes of Health

Publications: 27

Joan B. Geisbert

Joan B. Geisbert

The University of Texas Medical Branch at Galveston

Publications: 24

Andrew B. Ward

Andrew B. Ward

Scripps Research Institute

Publications: 23

Gary Wong

Gary Wong

Public Health Agency of Canada

Publications: 22

Something went wrong. Please try again later.